BLCO Stock Overview
Operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for BLCO from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Bausch + Lomb Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.00 |
| 52 Week High | US$21.69 |
| 52 Week Low | US$13.16 |
| Beta | 0.43 |
| 1 Month Change | -8.02% |
| 3 Month Change | -7.60% |
| 1 Year Change | 13.92% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -10.00% |
Recent News & Updates
Bausch + Lomb And Bausch Health: Some Incremental Progress As We Wait For Sale News
Dec 07Bausch + Lomb Corporation (NYSE:BLCO) Shares Fly 25% But Investors Aren't Buying For Growth
Oct 14
Recent updates
Bausch + Lomb And Bausch Health: Some Incremental Progress As We Wait For Sale News
Dec 07Bausch + Lomb Corporation (NYSE:BLCO) Shares Fly 25% But Investors Aren't Buying For Growth
Oct 14With Buyout Interest, Bausch + Lomb May Still Be Worth Interest At Current Levels
Sep 19Is Bausch + Lomb (NYSE:BLCO) Using Too Much Debt?
Sep 13Little Excitement Around Bausch + Lomb Corporation's (NYSE:BLCO) Revenues
Jun 22Bausch + Lomb's Bet-The-Farm Xiidra Acquisition Is Looking Questionable, But Miebo Could Make The Stock A Winner
May 24Bausch + Lomb Corporation (NYSE:BLCO) Shares Could Be 32% Below Their Intrinsic Value Estimate
Apr 30Is Bausch + Lomb (NYSE:BLCO) Using Too Much Debt?
Mar 25Many Still Looking Away From Bausch + Lomb Corporation (NYSE:BLCO)
Feb 19Hovering Around 52-Week Low, Bausch + Lomb May Be Poised For A Rebound
Jan 31Bausch + Lomb Corporation's (NYSE:BLCO) Intrinsic Value Is Potentially 34% Above Its Share Price
Jan 14Bausch + Lomb: Not A Good Time To Buy (Rating Downgrade)
Nov 08Bausch + Lomb: Growth Should Accelerate As Supply Issues Ease
Aug 09Bausch + Lomb Non-GAAP EPS of $0.23 beats by $0.01, revenue of $996M beats by $32.08M
Feb 22Shareholder Returns
| BLCO | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -3.2% | -1.5% | -2.4% |
| 1Y | 13.9% | 10.0% | 23.4% |
Return vs Industry: BLCO exceeded the US Medical Equipment industry which returned 10% over the past year.
Return vs Market: BLCO underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| BLCO volatility | |
|---|---|
| BLCO Average Weekly Movement | 5.2% |
| Medical Equipment Industry Average Movement | 7.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BLCO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BLCO's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1853 | 13,300 | Brent Saunders | www.bausch.com |
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.
Bausch + Lomb Corporation Fundamentals Summary
| BLCO fundamental statistics | |
|---|---|
| Market cap | US$6.34b |
| Earnings (TTM) | -US$368.00m |
| Revenue (TTM) | US$4.68b |
1.4x
P/S Ratio-17.2x
P/E RatioIs BLCO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BLCO income statement (TTM) | |
|---|---|
| Revenue | US$4.68b |
| Cost of Revenue | US$1.83b |
| Gross Profit | US$2.85b |
| Other Expenses | US$3.22b |
| Earnings | -US$368.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.04 |
| Gross Margin | 60.89% |
| Net Profit Margin | -7.86% |
| Debt/Equity Ratio | 69.5% |
How did BLCO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 10:28 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bausch + Lomb Corporation is covered by 24 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| Matt Miksic | Barclays |
| Craig Bijou | BofA Global Research |